Objective. GD with ATD-induced hepatic injury or
leukopenia occurs frequently in clinical practice. The purpose of the present study was to observe the clinical effect of
lithium carbonate on
hyperthyroidism in patients with GD with hepatic injury or
leukopenia. Methods. Fifty-one patients with GD with hepatic injury or
leukopenia participated in the study. All patients were treated with
lithium carbonate, in addition to hepatoprotective drugs or drugs that increase white blood cell count. Thyroid function, liver function, and white blood cells were measured. Clinical outcomes were observed after a 1-year follow-up. Results.
After treatment for 36 weeks, symptoms of
hyperthyroidism and the level of
thyroid hormones were improved and liver function, and white blood cells returned to a normal level. Twelve patients (23.5%) obtained clinical remission, 6 patients (11.8%) relapsed after withdrawal, 25 patients (49.0%) received radioiodine
therapy, and 8 patients (15.7%) underwent
surgical procedures after
lithium carbonate treatment. Conclusion.
Lithium carbonate has effects on the treatment of mild-to-moderate
hyperthyroidism caused by GD, and it is particularly suitable for patients with ATD-induced hepatic injury or
leukopenia.